Introduction
============

Osteosarcoma is the most common musculoskeletal malignancy in childhood and adolescence, characterized by early metastatic potential to the lung and poor prognosis.[@b1-ott-9-807] Nonsurgical therapeutic regimens, which are essential for osteosarcoma treatment, consist of chemotherapies composed of four agents. However, some osteosarcoma patients suffer from chemoresistance and require more aggressive chemotherapy strategies. Furthermore, there are still only limited biomarkers (that can be easily detected in the laboratory) for predicting outcomes or malignancy risk.

Single-nucleotide polymorphisms (SNPs) are genetic factors that have been associated with cancer risk or progression. Studies on SNPs in osteosarcoma are valuable for identifying prognostic markers. Efforts have focused on the identification of reliable associations between polymorphisms in different genes and osteosarcoma risk, such as *ERCC*,[@b2-ott-9-807] *VEGF*,[@b3-ott-9-807] *NAT2*,[@b4-ott-9-807] etc. However, studies on tumor suppressor gene polymorphisms in osteosarcoma are still limited.

The WW-domain containing oxidoreductase (*WWOX*) gene was demonstrated as a bona fide tumor suppressor gene, located on chromosome 16q23, spanning the common fragile site FRA16D.[@b5-ott-9-807] Evidence suggested that the *WWOX* gene plays an important role in preventing osteosarcoma tumorigenesis, as *WWOX* knockout mice showed significantly increased osteosarcoma susceptibility.[@b6-ott-9-807] Furthermore, in in vitro studies that increased expression of *WWOX* via transfection in tumor cell lines, tumor suppression activities were demonstrated.[@b7-ott-9-807],[@b8-ott-9-807] In addition, it was recently discovered that normally expressed *WWOX* inhibits osteosarcoma metastasis by modulating the function of some downstream proteins,[@b9-ott-9-807] and attenuation of the *WWOX* gene in osteosarcoma was associated with elevated tumorigenicity.[@b10-ott-9-807],[@b11-ott-9-807] Polymorphisms of the *WWOX* gene were also found to be related to risk of incidence or outcome of some other solid tumors, such as glioma,[@b12-ott-9-807] lung cancer,[@b13-ott-9-807] and thyroid cancer.[@b14-ott-9-807] Given the fact that *WWOX* plays a role in osteosarcoma, and that its gene polymorphisms were related to solid tumor risk, it is reasonable to hypothesize that *WWOX* polymorphisms are involved in progression osteosarcoma and that *WWOX* SNPs have potential as predicting factors.

In order to test the hypothesis that *WWOX* polymorphisms are correlated with osteosarcoma risk or progression in young Chinese individuals, four hospitals and institutions located in East China participated in this project and shared clinical data. A case-control study was launched, and we analyzed seven *WWOX* tagging SNPs in 276 osteosarcoma patients and 286 controls from a young East China population.

Material and methods
====================

Ethics approval
---------------

This case-control study was approved by the Ethics Committees of the four participating institutions (Shaoxing Shangyu People's Hospital, The Second Affiliated Hospital of Zhejiang University School of Medicine, The First People's Hospital of Wenling, and Shanghai Fudan University). All investigations were performed according to the Declaration of Helsinki. Written informed consent to participate in genomic research was obtained beforehand from each participant or their guardians.

Study participants
------------------

A total of 276 newly diagnosed primary osteosarcoma patients under the age of 20 years and 286 cancer-free controls were recruited in this study. All patients were diagnosed on the basis of pathologic evidence, and samples were collected during the period from February 2007 to September 2012. All patients underwent appropriate surgical resections (including limb salvage and amputation) by qualified orthopedic surgeons, as well as nonsurgical therapeutic regimens according to the guidelines, and were followed up regularly for at least 36 months. All clinical information was obtained from medical records. Cancer-free controls were recruited from nonpathological fracture cases, and were matched to patient cases by age and sex. Blood samples were obtained from each participant, and tumor tissues were preserved in liquid nitrogen.

DNA isolation
-------------

Whole DNA was isolated from blood samples by standard phenol--chloroform extraction and ethanol precipitation. Genomic DNA was isolated using a DNA Blood Mini Kit (Qiagen, Berlin, Germany). For tumor tissues, proteinase K digestion was performed followed by phenol--chloroform extraction.

SNP genotyping
--------------

Seven SNPs (*WWOX* rs10220974C\>T, rs12918952G\>A, rs3764340C\>G, rs1074963C\>G, rs383362G\>T, rs1424110A\>G, and rs12828A\>G) were selected for this study. Procedures were followed according to methods described in our previous study.[@b4-ott-9-807] Briefly, the Sequence Detection Software of the ABI StepOnePlus System (Thermo Fisher Scientific, Waltham, MA, USA) was used to collect data. TaqMan^®^ primers and probes were designed by the ABI Assays-by-Design custom service. All tests were performed on samples in triplicate and repeated twice. Amplification conditions were 95°C for 10 minutes, followed by 40 cycles at 95°C for 15 seconds, and at 60°C for 60 seconds. Plates were read with the corresponding ABI Software.

Haplotype analysis
------------------

The computational haplotyping method was utilized in this study. The seven SNPs were analyzed on SHEsis (<http://analysis.bio-x.cn/myAnalysis.php>) to identify frequent haplotypes (those with proportions over 3%).

Statistical analysis
--------------------

SPSS software (v21.0; IBM Corporation, Armonk, NY, USA) was used for statistical analysis. Similar to our previous research, statistical differences in distributions of selected variables, subject characteristics, and genotypes for *WWOX* were evaluated between osteosarcoma cases and controls by *χ*^2^ tests. Odd ratios (ORs) and 95% confidence intervals (95% CIs) were calculated to test for correlations between the seven SNPs and the risk of osteosarcoma incidence. Logistic regression analyses were performed to calculate crude ORs, and ORs were subsequently adjusted for age and sex. The Hardy--Weinberg equilibrium for SNPs was tested using Pearson's *χ*^2^ test. Statistical significance was defined as *P*\<0.05, and all analyses were two-sided.

Results
=======

Clinical features
-----------------

Clinical characteristics of the included samples are shown in [Table 1](#t1-ott-9-807){ref-type="table"}. In this study, we recruited 276 osteosarcoma cases and 286 controls. There were 162 male and 114 female patients. The median ages and ranges of the osteosarcoma cases and controls were 16 years (6--20 years) and 16.24 years (5--20 years), respectively. Tumors were graded according to the Enneking GTM system.[@b15-ott-9-807] No statistical differences in age or sex were found between the two groups (*P*=0.378 and 0.458, respectively).

Associations between *WWOX* polymorphisms and risk of osteosarcoma
------------------------------------------------------------------

The seven SNPs (rs10220974C\>T, rs12918952G\>A, rs3764340C\>G, rs1074963C\>G, rs383362G\>T, rs1424110A\>G, and rs12828A\>G) tested in this study are shown in [Table 2](#t2-ott-9-807){ref-type="table"}. Genotype distributions of each of the seven SNPs were in Hardy--Weinberg equilibrium in the control group (*P*=0.356, 0.800, 0.212, 0.641, 0.305, 0.261, and 0.152, respectively). For *WWOX* rs3764340C\>G, single locus analyses showed no statistical difference in genotype between cases and controls. However, when the CC homozygote genotype was used as the reference group, the CG genotype showed significantly increased risk of osteosarcoma (CG vs CC: crude OR =1.73, 95% CI =1.15--2.61, *P*=0.009; adjusted OR =1.74, 95% CI =1.15--2.63, *P*=0.009). The GG genotype was not related to risk of osteosarcoma (although a borderline difference was found). In the dominant model, an even stronger statistical difference was detected (CG/GG vs CC: crude OR =1.82, 95% CI =1.23--2.69, *P*=0.003; adjusted OR =1.82, 95% CI =1.22--2.70, *P*=0.003). In the recessive model, no statistically significant differences were found.

Similar to rs3764340C\>G, there was an association between the *WWOX* rs383362G\>T SNP and osteosarcoma risk. The GT genotype was associated with an increased risk of osteosarcoma (GT vs GG: crude OR =1.59, 95% CI =1.07--2.35, *P*=0.022; adjusted OR =1.56, 95% CI =1.05--2.32, *P*=0.027). Although no correlation with osteosarcoma risk was found for the TT genotype, the dominant model (GT/TT) showed evidence for association with risk of osteosarcoma (GT/TT vs GG: crude OR =1.60, 95% CI =1.10--2.34, *P*=0.015; adjusted OR =1.57, 95% CI =1.07--2.30, *P*=0.020).

No association for osteosarcoma susceptibility in the young Chinese population was found for the remaining five SNPs (rs10220974C\>T, rs12918952G\>A, rs1074963C\>G, rs1424110A\>G, and rs12828A\>G).

Associations between *WWOX* polymorphisms and stage or metastasis of osteosarcoma
---------------------------------------------------------------------------------

Data on clinical features (location, surgical stage, operation method, and metastasis) of osteosarcoma cases were collected to reliably investigate the relationship between SNPs and incidence of osteosarcoma ([Table 3](#t3-ott-9-807){ref-type="table"}). For *WWOX* rs3764340C\>G, the frequency of the genotype CG at late Enneking stages (28.63%) was greater when compared with early-stage cases (9.52%), and a statistical difference in frequency distribution was found (*P*=0.033). Moreover, a similar result was shown for metastasis. The genotype CG displayed higher frequency (32.08%) in metastatic cases compared with metastasis-free cases (24.22%), and the difference in frequency distribution was statistically significant (*P*=0.027).

For *WWOX* rs383362G\>T, however, no correlation was found between the rs383362 SNP and clinical characteristics. Although the rs383362G\>T SNP was found to be related to osteosarcoma susceptibility, it was not associated with osteosarcoma location (*P*=0.357), stage (*P*=0.939), operation method (*P*=0.141), or metastasis (*P*=0.539) (data shown in [Table 4](#t4-ott-9-807){ref-type="table"}). The confounding variables are listed in [Tables 5](#t5-ott-9-807){ref-type="table"} and [6](#t6-ott-9-807){ref-type="table"}.

Haplotype analyses showed statistical differences between cases and controls
----------------------------------------------------------------------------

Online analyses of seven SNPs revealed eight frequent haplotypes (frequency over 3%): CGCCGAG, CGCGGAA, CGCGGAG, CGCGGGA, CGCGGGG, CGCGTGG, CGGGAG, and CGGGGG ([Table 7](#t7-ott-9-807){ref-type="table"}). Among them, CGCGGAG and CGCGTGG showed statistically significant differences between cases and controls (*P*\<0.001, 95% CI =0.41--0.75; *P*=0.005, 95% CI =1.30--5.23, respectively).

Discussion
==========

Studies on new therapeutic strategies against osteosarcoma are emerging, especially for different kinds of immunotherapy, which are showing promising results.[@b16-ott-9-807]--[@b18-ott-9-807] However, prediction factors, especially those that can be easily detected in laboratory assays, remain limited. Recently, several studies have revealed potential factors that may be utilized to predict osteosarcoma outcome or metastasis risk,[@b19-ott-9-807],[@b20-ott-9-807] but studies based on clinical data have still been limited (or have sometimes had controversial results). Given that osteosarcoma is not a common malignancy, we collected blood samples and tumor tissues of osteosarcoma patients from different hospitals located in East China (which has a stable population of over 100 million) and tried to identify indicators predictive of disease risk. In our previous study, our colleagues found that *NAT2* gene polymorphisms were associated with osteosarcoma risk,[@b4-ott-9-807] but the reason for the effects of *NAT2* polymorphisms on osteosarcoma risk and outcome has remained unclear. We therefore continued to search for genes involved in osteosarcoma pathogenesis using our blood and tissue sample bank.

Currently, clinicians usually make therapeutic plans for osteosarcomas based on imaging data and clinical symptoms, while laboratory examinations are seldom used. If effective genotype analyses could be established, clinicians would have more evidence for making decisions on more radical therapeutic regimens for high-risk patients. In this case-control study, we discovered that *WWOX* rs3764340C\>G and rs383362G\>T SNPs were associated with increased risk of osteosarcoma. Furthermore, to determine if *WWOX* SNPs are associated with outcomes of osteosarcoma, we analyzed SNPs with clinical data, including age, sex, location, grade, operation method, and metastasis. Here, we demonstrated that rs3764340C\>G was related to the grade of osteosarcoma and metastasis. Moreover, although rs383362G\>T was found to be associated with osteosarcoma risk, no correlation was found in grade or metastasis risk. As *WWOX* is an established tumor suppressor gene, our results, indicating that polymorphisms in this gene are related to osteosarcoma, seem reasonable. We therefore believe that people with particular *WWOX* genotypes will have corresponding osteosarcoma risks and outcomes.

In addition to SNP analyses, haplotyping was performed. The haplotype CGCGGAG was more frequent in normal individuals, while CGCGTGG (which replaced G with T) was more common in osteosarcoma patients. This result provides evidence that rs383362G\>T plays a role in osteosarcoma.

Other studies on *WWOX* rs3764340 revealed similar results. The CG/GG genotype of rs3764340 was accompanied by elevated risk of gastric cardia adenocarcinoma,[@b21-ott-9-807] lung cancer,[@b13-ott-9-807] and thyroid carcinoma,[@b14-ott-9-807] consistent with our results. Thus, we propose that carriers of the G allele of *WWOX* rs3764340 may have increased cancer risk.

There are some limitations to our study. First, all blood or tumor tissue samples were collected from hospitals and, consequently, inherent bias might have affected our results. Second, due to the low morbidity of osteosarcoma, the sample size was limited, especially for homozygotic cases, which limits the statistical power. Third, as over half the recruited patients were still alive, we were not able to provide data analysis on survival. We will continue collecting samples and tracking clinical data to provide updated research results. Indeed, given the low morbidity of osteosarcoma (as low as around 5 per million), a prospective study would not be easy to implement and, consequently, we have no plans for such a study at present.

In summary, this study demonstrates that *WWOX* rs3764340 and rs383362 polymorphisms are associated with osteosarcoma susceptibility in young Chinese individuals. The *WWOX* rs3764340 polymorphism was thus correlated with surgical grade and metastatic risk of osteosarcoma.
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###### 

General characteristics of the subjects

  Variables            Osteosarcoma cases, n (%)   Controls, n (%)   *P*-value
  -------------------- --------------------------- ----------------- -----------
  Age (mean ± SD)      16±3.28                     16.24±3.30        0.378
  Sex                                                                
   Male                162 (58.70)                 159 (55.59)       0.458
   Female              114 (41.30)                 127 (44.41)       
  Location                                                           
   Trunk               34 (12.32)                                    
   Limbs               242 (87.68)                                   
  Enneking stages                                                    
   IA or IB            42 (15.22)                                    
   IIA or IIB or III   234 (84.78)                                   
  Operation                                                          
   Amputation          55 (19.93)                                    
   Limb salvage        221 (80.07)                                   
  Metastasis                                                         
   Yes                 53 (19.20)                                    
   No                  223 (80.80)                                   

**Abbreviation:** SD, standard deviation.

###### 

Logistic regression analyses of correlations between *WWOX* rs10220974C\>T, rs12918952G\>A, rs3764340C\>G, rs1074963C\>G, rs383362G\>T, rs1424110A\>G, and rs12828A\>G polymorphisms and risk of osteosarcoma

  *WWOX* genotype          Cases (N=276)   Controls (N=286)   Crude OR (95% Cl)   *P*-value   Adjusted OR (95% Cl)   *P*-value                                                              
  ------------------------ --------------- ------------------ ------------------- ----------- ---------------------- ------------------------------------------------- -------------------- -------------------------------------------------
  *WWOX* rs10220974 C\>T                                                                                                                                                                    
   CC                      211             76.45              228                 79.72       1.00                                                                     1.00                 
   CT                      61              22.10              53                  18.53       1.24 (0.82--1.88)      0.301                                             1.24 (0.82--1.88)    0.308
   TT                      4               1.45               5                   1.75        0.86 (0.23--3.26)      0.830                                             0.85 (0.23--3.22)    0.812
   CT + TT                 65              23.55              58                  20.28       1.21 (0.81--1.81)      0.349                                             1.21 (0.81--1.80)    0.360
   CC + CT                 272             98.55              281                 98.25       1.00                                                                     1.00                 
   TT                      4               1.45               5                   1.75        0.83 (0.22--3.11)      0.78                                              0.81 (0.22--3.07)    0.76
  *WWOX* rs12918952 G\>A                                                                                                                                                                    
   GG                      251             90.94              257                 89.86       1.00                                                                     1.00                 
   GA                      23              8.33               28                  9.79        0.84 (0.47--1.50)      0.557                                             0.83 (0.46--1.48)    0.520
   AA                      2               0.72               1                   0.35        2.05 (0.19--22.73)     0.559                                             2.25 (0.20--25.13)   0.509
   GA + AA                 25              9.05               29                  10.14       0.88 (0.50--1.55)      0.664                                             0.87 (0.50--1.54)    0.638
   GG + GA                 274             99.28              285                 99.65       1.00                                                                     1.00                 
   AA                      2               0.72               1                   0.35        2.08 (0.19--23.07)     0.551                                             2.29 (0.21--25.51)   0.501
  *WWOX* rs3764340C\>G                                                                                                                                                                      
   CC                      194             70.29              232                 81.12       1.00                                                                     1.00                 
   CG                      71              25.72              49                  17.13       1.73 (1.15--2.61)      0.009[\*](#tfn3-ott-9-807){ref-type="table-fn"}   1.74 (1.15--2.63)    0.009[\*](#tfn3-ott-9-807){ref-type="table-fn"}
   GG                      11              3.99               5                   1.75        2.63 (0.90--7.70)      0.078                                             2.57 (0.88--7.56)    0.086
   CG + GG                 82              29.71              54                  18.88       1.82 (1.23--2.69)      0.003[\*](#tfn3-ott-9-807){ref-type="table-fn"}   1.82 (1.22--2.70)    0.003[\*](#tfn3-ott-9-807){ref-type="table-fn"}
   CC + CG                 265             96.01              281                 98.25       1.00                                                                     1.00                 
   GG                      11              3.99               5                   1.75        2.33 (0.80--6.80)      0.121                                             2.27 (0.78--6.63)    0.135
  *WWOX* rs1074963C\>G                                                                                                                                                                      
   CC                      4               1.45               7                   2.45        1.00                                                                     1.00                 
   CG                      72              26.09              69                  24.13       1.83 (0.51--6.52)      0.354                                             1.93 (0.54--6.93)    0.312
   GG                      200             72.46              210                 73.43       1.67 (0.48--5.78)      0.421                                             1.79 (0.51--6.24)    0.363
   CG + GG                 272             98.55              279                 97.55       1.71 (0.49--5.89)      0.398                                             1.83 (0.53--6.34)    0.344
   CC + CG                 76              27.54              76                  26.58       1.00                                                                     1.00                 
   GG                      200             72.46              210                 73.43       0.95 (0.66--1.38)      0.797                                             0.97 (0.67--1.41)    0.862
  *WWOX* rs383362G\>T                                                                                                                                                                       
   GG                      190             68.84              223                 77.97       1.00                                                                     1.00                 
   GT                      77              27.90              57                  19.93       1.59 (1.07--2.35)      0.022[\*](#tfn3-ott-9-807){ref-type="table-fn"}   1.56 (1.05--2.32)    0.027[\*](#tfn3-ott-9-807){ref-type="table-fn"}
   TT                      9               3.26               6                   2.10        1.76 (0.62--5.04)      0.292                                             1.65 (0.57--4.77)    0.354
   GT + TT                 86              31.16              63                  22.03       1.60 (1.10--2.34)      0.015[\*](#tfn3-ott-9-807){ref-type="table-fn"}   1.57 (1.07--2.30)    0.020[\*](#tfn3-ott-9-807){ref-type="table-fn"}
   GG + GT                 267             96.74              280                 97.90       1.00                                                                     1.00                 
   TT                      9               3.26               6                   2.10        1.57 (0.55--4.48)      0.396                                             1.46 (0.51--4.21)    0.480
  *WWOX* rs1424110A\>G                                                                                                                                                                      
   AA                      88              31.88              108                 37.76       1.00                                                                     1.00                 
   AG                      136             49.28              127                 44.41       1.31 (0.91--1.91)      0.149                                             1.31 (0.90--1.90)    0.154
   GG                      52              18.84              51                  17.83       1.25 (0.78--2.02)      0.358                                             1.25 (0.78--2.02)    0.356
   AG + GG                 188             68.12              178                 62.24       1.30 (0.92--1.84)      0.144                                             1.29 (0.91--1.83)    0.148
   AA + AG                 224             81.16              235                 82.17       1.00                                                                     1.00                 
   GG                      52              18.84              51                  17.83       1.07 (0.70--1.64)      0.757                                             1.07 (0.70--1.65)    0.747
  *WWOX* rs12828A\>G                                                                                                                                                                        
   AA                      20              7.25               24                  8.39        1.00                                                                     1.00                 
   AG                      125             45.29              135                 47.20       1.11 (0.59--2.11)      0.747                                             1.09 (0.57--2.08)    0.796
   GG                      131             47.46              127                 44.41       1.24 (0.65--2.35)      0.515                                             1.21 (0.63--2.30)    0.570
   AG + GG                 256             92.75              262                 91.61       1.17 (0.63--2.18)      0.614                                             1.15 (0.62--2.13)    0.668
   AA + AG                 145             52.54              159                 55.59       1.00                                                                     1.00                 
   GG                      131             47.46              127                 44.41       1.13 (0.81--1.58)      0.467                                             1.12 (0.80--1.56)    0.502

**Notes:** ORs were adjusted for age and sex.

Statistically significant (*P*\>0.05).

**Abbreviations:** OR, odds ratio; CI, confidence interval.

###### 

Association between genotype frequencies of *WWOX* rs3764340 and clinical features in osteosarcoma cases

  Variables            n     CC, n (%)     CG, n (%)    GG, n (%)   *P*-value
  -------------------- ----- ------------- ------------ ----------- -------------------------------------------------
  Location                                                          
   Trunk               34    26 (76.47)    5 (14.71)    3 (8.82)    0.115
   Limbs               242   168 (69.42)   66 (27.27)   8 (3.31)    
  Enneking stages                                                   
   IA or IB            42    36 (85.71)    4 (9.52)     2 (4.76)    0.033[\*](#tfn5-ott-9-807){ref-type="table-fn"}
   IIA or IIB or III   234   158 (67.52)   67 (28.63)   9 (3.85)    
  Operation                                                         
   Amputation          55    42 (76.36)    10 (18.18)   3 (5.45)    0.324
   Limb salvage        221   152 (68.78)   61 (27.60)   8 (3.62)    
  Metastasis                                                        
   Yes                 53    31 (58.49)    17 (32.08)   5 (9.43)    0.027[\*](#tfn5-ott-9-807){ref-type="table-fn"}
   No                  223   163 (73.08)   54 (24.22)   6 (2.69)    

**Note:**

Statistically significant (*P*\>0.05).

###### 

Association between genotype frequencies of *WWOX* rs383362 and clinical features in osteosarcoma cases

  Variables            n     GG n (%)      GT n (%)     TT n (%)   *P*-value
  -------------------- ----- ------------- ------------ ---------- -----------
  Location                                                         
   Trunk               34    20 (58.8)     13 (38.24)   1 (2.94)   0.357
   Limbs               242   170 (70.25)   64 (26.45)   8 (3.31)   
  Enneking stages                                                  
   IA or IB            42    29 (69.05)    12 (28.57)   1 (2.38)   0.939
   IIA or IIB or III   234   161 (68.80)   65 (27.78)   9 (3.42)   
  Operation                                                        
   Amputation          55    32 (58.18)    20 (36.36)   3 (5.45)   0.141
   Limb salvage        221   158 (71.49)   57 (25.79)   6 (2.71)   
  Metastasis                                                       
   Yes                 53    35 (66.04)    15 (28.30)   3 (5.66)   0.539
   No                  223   155 (69.51)   62 (27.80)   6 (2.69)   

###### 

Confounding variables (Enneking stages)

  Confounding variables    IA or IB cases, n (%)   IIA or IIB or III cases, n (%)   *P*-value
  ------------------------ ----------------------- -------------------------------- -----------
  Age, mean ± SD (years)   16.50±2.84              15.91±3.35                       0.284
  Sex                                                                               
   Male                    21 (50)                 141 (60.26)                      0.214
   Female                  21 (50)                 93 (39.74)                       

**Abbreviation:** SD, standard deviation.

###### 

Confounding variables (metastasis)

  Confounding variables    Metastasis cases, n (%)   Nonmetastasis cases, n (%)   *P*-value
  ------------------------ ------------------------- ---------------------------- -----------
  Age, mean ± SD (years)   15.72±3.57                16.07±3.21                   0.485
  Sex                                                                             
   Male                    34 (64.15)                128 (57.40)                  0.370
   Female                  19 (35.85)                95 (42.60)                   

**Abbreviation:** SD, standard deviation.

###### 

Haplotype analysis

  Haplotype   Cases (N=276)   Controls (N=286)   *P*-value                                           OR (95% Cl)
  ----------- --------------- ------------------ --------------------------------------------------- -------------------
  CGCCGAG     16.55 (0.03)    24.22 (0.04)       0.236                                               0.68 (0.36--1.29)
  CGCGGAA     56.81 (0.10)    56.60 (0.01)       0.917                                               1.02 (0.69--1.52)
  CGCGGAG     105.19 (0.19)   159.12 (0.28)      \<0.001[\*](#tfn8-ott-9-807){ref-type="table-fn"}   0.56 (0.41--0.75)
  CGCGGGA     41.18 (0.08)    47.53 (0.08)       0.522                                               0.87 (0.56--1.35)
  CGCGGGG     66.81 (0.12)    89.56 (0.16)       0.055                                               0.71 (0.50--1.01)
  CGCGTGG     28.45 (0.05)    11.58 (0.02)       0.005[\*](#tfn8-ott-9-807){ref-type="table-fn"}     2.60 (1.30--5.23)
  CGGGGAG     20.08 (0.04)    11.09 (0.02)       0.092                                               1.88 (0.89--3.97)
  CGGGGGG     18.96 (0.03)    10.09 (0.02)       0.086                                               1.95 (0.90--4.24)

**Note:**

Statistically significant (*P*\<0.05).

**Abbreviations:** OR, odds ratio; CI, confidence interval.
